Sacubitril valsartan sodium tablets are broken down into valsartan and sacubitril (re-metabolized to LBQ657) with half-lives of 9.9h, 1.4h, and 11.5h, respectively. Sacubitril Valsartan sodium tablets are broken down in vivo into valsartan and sacubitril, which is further metabolized to the active metabolite LBQ657, with half-lives of 9.9 h, 1.4 h, and 11.5 h for valsartan, sacubitril, and LBQ657, respectively. Sacubitril is an enkephalinase inhibitor and valsartan is an angiotensin receptor inhibitor. Sacubitril valsartan is clinically used for the treatment of patients with chronic heart failure with a reduced ejection fraction, and also for the treatment of essential hypertension. It should be noted that sacubatril valsartan is contraindicated in people with a history of hypersensitivity to the components of this drug, women with mid- to late-stage pregnancy, and people with severe hepatic impairment. It can not be combined with ACEIs such as Benadryl, nor can it be used in patients with hereditary or idiopathic angioedema, and in diabetic patients it can not be combined with Aliskiren. Adverse reactions such as angioedema, hypotension, hyperkalemia, renal impairment may occur in the use of sacubitril valsartan, which should be used under medical supervision. If you feel unwell, go to the hospital promptly.